Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LUNG 
Pulmonx Corp (LUNG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: LUNG (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.75
1 Year Target Price $5.75
| 4 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.99% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 78.23M USD | Price to earnings Ratio - | 1Y Target Price 5.75 |
Price to earnings Ratio - | 1Y Target Price 5.75 | ||
Volume (30-day avg) 7 | Beta 0.21 | 52 Weeks Range 1.47 - 9.37 | Updated Date 11/7/2025 |
52 Weeks Range 1.47 - 9.37 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-29 | When - | Estimate -0.42 | Actual - |
Profitability
Profit Margin -62.88% | Operating Margin (TTM) -62.05% |
Management Effectiveness
Return on Assets (TTM) -21.57% | Return on Equity (TTM) -66.88% |
Valuation
Trailing PE - | Forward PE 28.33 | Enterprise Value 41464679 | Price to Sales(TTM) 0.86 |
Enterprise Value 41464679 | Price to Sales(TTM) 0.86 | ||
Enterprise Value to Revenue 0.46 | Enterprise Value to EBITDA -5.62 | Shares Outstanding 40746556 | Shares Floating 39663513 |
Shares Outstanding 40746556 | Shares Floating 39663513 | ||
Percent Insiders 4.27 | Percent Institutions 89.51 |
Upturn AI SWOT
Pulmonx Corp
Company Overview
History and Background
Pulmonx Corp. was founded in 1995. It's a medical technology company focused on developing and commercializing minimally invasive treatments for severe lung disease.
Core Business Areas
- Interventional Pulmonology: Pulmonx develops and markets the Zephyr Endobronchial Valve (EBV) system for treating severe emphysema.
Leadership and Structure
The leadership team includes executives overseeing areas like sales, marketing, research and development, and finance. The company has a board of directors responsible for governance.
Top Products and Market Share
Key Offerings
- Zephyr Endobronchial Valve (EBV): The Zephyr EBV is a minimally invasive device used to treat severe emphysema by blocking airflow to diseased regions of the lung, allowing healthier regions to expand and improve breathing. Limited data on exact market share, but the Zephyr EBV is a leading product in the bronchoscopic lung volume reduction market. Competitors include PneumRx (acquired by BTG) and other therapies for COPD/emphysema.
Market Dynamics
Industry Overview
The industry involves medical devices and therapies for respiratory diseases, particularly COPD and emphysema. It is characterized by ongoing innovation, regulatory approvals, and reimbursement challenges.
Positioning
Pulmonx is positioned as a leader in minimally invasive bronchoscopic lung volume reduction with the Zephyr EBV. Their competitive advantage lies in clinical evidence, physician training programs, and established market presence.
Total Addressable Market (TAM)
The TAM is estimated to be several billion dollars, consisting of the number of individuals suffering from severe emphysema and the cost of the Zephyr EBV procedure. Pulmonx is positioned to capture a significant share of this TAM through ongoing market penetration and expansion of treatment access.
Upturn SWOT Analysis
Strengths
- Proprietary Technology
- Strong Clinical Evidence
- Established Market Presence
- Minimally Invasive Approach
Weaknesses
- Limited Product Portfolio
- Reliance on Reimbursement
- High Procedure Cost
- Dependence on Physician Training
Opportunities
- Expanding Treatment Access
- Increasing Market Penetration
- Developing New Applications
- Entering New Markets
Threats
- Competition from Alternative Therapies
- Regulatory Changes
- Reimbursement Cuts
- Technological Advancements by Competitors
Competitors and Market Share
Key Competitors
- BSX
- ABT
- MEDP
Competitive Landscape
Pulmonx faces competition from larger medical device companies with broader product portfolios and established market presence. However, Pulmonx's competitive advantage lies in its proprietary Zephyr EBV technology and focus on minimally invasive bronchoscopic lung volume reduction.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increased adoption of the Zephyr EBV and market expansion.
Future Projections: Future growth is projected to come from continued market penetration, expansion into new geographies, and development of new products or applications.
Recent Initiatives: Recent strategic initiatives include expanding physician training programs, investing in clinical research, and pursuing regulatory approvals in new markets.
Summary
Pulmonx is a specialized medical device company focused on treating severe emphysema with its Zephyr EBV. The device has strong clinical evidence supporting its efficacy and the company is working to expand market access. However, reimbursement challenges and competition from larger companies present significant headwinds. Future growth depends on market penetration, new applications, and new markets.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Investor Relations
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share and financial data are estimates and may not be exact.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pulmonx Corp
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2020-10-01 | CEO, President & Director Mr. Glendon E. French | ||
Sector Healthcare | Industry Medical Devices | Full time employees 291 | Website https://pulmonx.com |
Full time employees 291 | Website https://pulmonx.com | ||
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.